{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:48Z","timestamp":1793228688497,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Proton pump inhibitors (PPIs) are acid suppressants that are frequently prescribed in many countries to reduce heartburn. A potassium-competitive acid blocker (P-CAB; tegoprazan) was launched relatively recently that also inhibits gastric acid secretion. This study aimed to compare the hepatotoxicity of the six existing PPIs with P-CAB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study was conducted between January 2019 and December 2020 and included data from the total population of 50 million inhabitants in Korea. Propensity score (PS) matching was performed using 10 variables, and the differences in hepatotoxicity between P-CAB and the six PPIs were compared in a similar distribution. The primary endpoint was hepatotoxicity which included toxic liver disease, hepatitis, hepatic failure, liver transplantation, and other liver diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The risk ratios (RR) of tegoprazan vs. the six PPIs (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) were all significant [RR: 0.70 (95% CI: 0.69\u20130.72), 0.81 (95% CI: 0.79\u20130.83), 0.61 (95% CI: 0.59\u20130.63), 1.17 (95% CI: 1.13\u20131.20), 0.61 (95% CI: 0.59\u20130.62), and 0.73 (95% CI: 0.71\u20130.75), respectively]. The risk ratio of tegoprazan vs. the six existing PPIs was 0.73 (95% CI: 0.72\u20130.75). The hazard ratios (HRs) of hepatotoxicity of the six PPIs to tegoprazan showed significantly higher values apart from omeprazole (HR: dexlansoprazole, 1.13; esomeprazole, 1.04; lansoprazole, 1.25; omeprazole, 0.77; pantoprazole, 1.26; rabeprazole, 1.15, respectively, and the six existing PPIs, 1.10).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using a large-scale data cohort analysis consisting of 50 million Koreans, tegoprazan did not induce higher hepatotoxicity compared with the six conventional PPIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1076356","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:58:55Z","timestamp":1673420335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study"],"prefix":"10.3389","volume":"9","author":[{"given":"Min-Gul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jin","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Woo","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s15010-022-01948-y.","article-title":"Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry","author":"Le Thi","year":"2022","journal-title":"Infection."},{"key":"B3","volume-title":"Drug Class Review: Proton Pump Inhibitors: Final Report Update 5","author":"McDonagh","year":"2009"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1097\/MCG.0b013e31803233b7","article-title":"The gastric H, K ATPase as a drug target: past, present, and future","volume":"41","author":"Sachs","year":"2007","journal-title":"J Clin Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A Study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals","volume":"337","author":"Hori","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers-are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J Neurogastroenterol Motil."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","article-title":"randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis","volume":"5","author":"Kahrilas","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","article-title":"randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease","volume":"103","author":"Dent","year":"2008","journal-title":"ACG."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1756283X17745776","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Ther Adv Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","article-title":"Acute liver failure","volume":"394","author":"Stravitz","year":"2019","journal-title":"Lancet."},{"key":"B13","first-page":"756","article-title":"Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation","volume":"74","author":"Heidelbaugh","year":"2006","journal-title":"Am Fam Physician."},{"key":"B14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J Pharmacol Exp Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"Cmaj."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1002\/(SICI)1099-1557(199808)7:1+<S41::AID-PDS347>3.0.CO;2-2","article-title":"Omeprazole-induced hepatotoxicity? A case report","volume":"7","author":"Christe","year":"1998","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13737","article-title":"Pantoprazole-induced autoimmune chronic hepatitis","volume":"38","author":"Meunier","year":"2018","journal-title":"Liver Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00508-014-0535-3","article-title":"Liver hepatotoxicity associated with pantoprazole: a rare case report","volume":"126","author":"Aslan","year":"2014","journal-title":"Wien Klin Wochenschr."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:59:00Z","timestamp":1673420340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":20,"alternative-id":["10.3389\/fmed.2022.1076356"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1076356","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"article-number":"1076356"}}